Åsa H Everhov1,2, Sara Ekberg3, Angelica Lindén Hirschberg4, Karin Bergmark5, Angelique Flöter Rådestad4, Ingrid Glimelius3,6, Karin E Smedby3. 1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. asa.hallqvist-everhov@ki.se. 2. Department of Surgery, South Hospital, SE 118 61, Stockholm, Sweden. asa.hallqvist-everhov@ki.se. 3. Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. 4. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. 5. Department of Oncology, Sahlgrenska Academy, Gothenburg, Sweden. 6. Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden.
Abstract
PURPOSE: The aim of the present study was to examine the risk of lost workdays due to sick leave and disability pension by treatment modality and relapse in a population-based cohort of cervical cancer survivors versus matched comparators. METHODS: We identified 1971 cervical cancer patients aged ≤60 years (median 42) at diagnosis in Sweden 2003-2009 and 9254 population comparators. Information on sociodemographic and clinical characteristics, sick leave, and disability pension was retrieved from nationwide prospective registers. Differences in the annual mean number of lost workdays were calculated by linear regression, and hazard ratios (HRs) of disability pension were calculated by Cox regression analysis, with follow-up through September 2013. RESULTS: Cervical cancer patients had more lost workdays annually than comparators up to 8 years following diagnosis. Relapse-free patients had more lost workdays than comparators up to 4 years. Risk of disability pension during follow-up was increased among the relapse-free patients treated with hysterectomy (HR 1.8 [95 % confidence interval (CI) 1.1-2.8]), hysterectomy plus chemotherapy and/or radiotherapy (HR 2.5 [95 % CI 1.2-5.4]), or chemotherapy and/or radiotherapy alone (HR 3.0 [95 % CI 1.3-6.8]), compared with the population. Women treated with fertility-sparing surgery did not have more lost workdays than the population beyond the first year and were not at increased risk of disability pension. CONCLUSION: We observed a long-standing increased risk of lost workdays among cervical cancer patients, overall, as well as among relapse-free patients. IMPLICATIONS FOR CANCER SURVIVORS: Extensive but not limited treatment was associated with increased risk of lost workdays, possibly reflecting an association between treatment side effects and work ability.
PURPOSE: The aim of the present study was to examine the risk of lost workdays due to sick leave and disability pension by treatment modality and relapse in a population-based cohort of cervical cancer survivors versus matched comparators. METHODS: We identified 1971 cervical cancerpatients aged ≤60 years (median 42) at diagnosis in Sweden 2003-2009 and 9254 population comparators. Information on sociodemographic and clinical characteristics, sick leave, and disability pension was retrieved from nationwide prospective registers. Differences in the annual mean number of lost workdays were calculated by linear regression, and hazard ratios (HRs) of disability pension were calculated by Cox regression analysis, with follow-up through September 2013. RESULTS: Cervical cancerpatients had more lost workdays annually than comparators up to 8 years following diagnosis. Relapse-free patients had more lost workdays than comparators up to 4 years. Risk of disability pension during follow-up was increased among the relapse-free patients treated with hysterectomy (HR 1.8 [95 % confidence interval (CI) 1.1-2.8]), hysterectomy plus chemotherapy and/or radiotherapy (HR 2.5 [95 % CI 1.2-5.4]), or chemotherapy and/or radiotherapy alone (HR 3.0 [95 % CI 1.3-6.8]), compared with the population. Women treated with fertility-sparing surgery did not have more lost workdays than the population beyond the first year and were not at increased risk of disability pension. CONCLUSION: We observed a long-standing increased risk of lost workdays among cervical cancerpatients, overall, as well as among relapse-free patients. IMPLICATIONS FOR CANCER SURVIVORS: Extensive but not limited treatment was associated with increased risk of lost workdays, possibly reflecting an association between treatment side effects and work ability.
Authors: Q D Pieterse; C P Maas; M M ter Kuile; M Lowik; M A van Eijkeren; J B M Z Trimbos; G G Kenter Journal: Int J Gynecol Cancer Date: 2006 May-Jun Impact factor: 3.437
Authors: Michael Feuerstein; Briana L Todd; Michal C Moskowitz; Gina L Bruns; Mallori R Stoler; Thomas Nassif; Xinhua Yu Journal: J Cancer Surviv Date: 2010-10-14 Impact factor: 4.442
Authors: Ida J Korfage; Marie-Louise Essink-Bot; Floortje Mols; Lonneke van de Poll-Franse; Roy Kruitwagen; Marjolein van Ballegooijen Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-25 Impact factor: 7.038
Authors: Ruth A Kleinerman; Susan A Smith; Eric Holowaty; Per Hall; Eero Pukkala; Leila Vaalavirta; Marilyn Stovall; Rita Weathers; Ethel Gilbert; Berthe M P Aleman; Magnus Kaijser; Michael Andersson; Hans Storm; Heikki Joensuu; Charles F Lynch; Graça M Dores; Lois B Travis; Lindsay M Morton; Rochelle E Curtis Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-22 Impact factor: 7.038
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: A G E M de Boer; J H A M Verbeek; E R Spelten; A L J Uitterhoeve; A C Ansink; T M de Reijke; M Kammeijer; M A G Sprangers; F J H van Dijk Journal: Br J Cancer Date: 2008-03-18 Impact factor: 7.640
Authors: Fabiana Maluf Rabacow; Renata Bertazzi Levy; Paulo Rossi Menezes; Olinda do Carmo Luiz; Ana Maria Malik; Alex Burdorf Journal: BMC Public Health Date: 2014-04-06 Impact factor: 3.295
Authors: Alv A Dahl; Anne Gry Bentzen; Sophie D Fosså; Siri Lothe Hess; Rita Steen; Cecilie E Kiserud Journal: J Cancer Surviv Date: 2020-04-11 Impact factor: 4.442